Replimune Group, Inc. (REPL)
9.95
-0.23
(-2.26%)
USD |
NASDAQ |
Dec 15, 16:00
9.95
0.00 (0.00%)
Pre-Market: 09:26
Replimune Group Cash from Investing (Quarterly): 84.17M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Rapt Therapeutics, Inc. | 8.466M |
| Olema Pharmaceuticals, Inc. | 17.27M |
| CorMedix, Inc. | -291.32M |
| Verastem, Inc. | -8.279M |
| Anavex Life Sciences Corp. | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -81.21M |
| Cash from Financing (Quarterly) | 0.324M |
| Free Cash Flow | -269.69M |
| Free Cash Flow Per Share (Quarterly) | -0.8982 |
| Free Cash Flow to Equity (Quarterly) | -82.55M |
| Free Cash Flow to Firm (Quarterly) | -80.56M |
| Free Cash Flow Yield | -31.52% |